6505--Ustekinumab or Biosimilar Syringes/Vials 36E79725R0045
Summary
AI-generated · Aug 23, 2025Unrestricted procurement of Ustekinumab syringes and vials (brand-name or biosimilar) to support supply for the VA and participating agencies, under a single contract for one year with four option years. Items will be distributed through the agencies’ Prime Vendor Programs, and the award will go to a bidder who can provide an uninterrupted supply. Offerors must identify the exact drug name to appear on the label and provide a unique NDC; only the contractor’s label with that NDC may appear on the product, with no other label applied over it. If a strength is available as both a syringe and a vial, both forms must be offered at the same price. The three line items cover Ustekinumab at 5 mg/mL (26 mL), 45 mg/0.5 mL, and 90 mg/1 mL syringe, with projected annual usage of 2,917; 8,925; and 38,028 units respectively. Biosimilar products must be FDA-licensed biologics and listed as biosimilars in the FDA Purple Book; if both syringe and vial exist for a strength, both must be offered at the same price.
New information includes an extension of the offer due date and updated estimates for line item 3; no awards have been posted yet. Proposals will be submitted electronically (no paper copies or phone requests); monitor SAM.gov for amendments and download solicitation documents.
PRE-SOLICITATION NOTICE: The VA National Acquisition Center intends to issue Request for Proposal (RFP) 36E79725R0045 for an unrestricted procurement for Ustekinumab Sytinges/Vials, for the Department of Veterans Affairs (VA) (inclusive of Consolidated Mail Order Pharmacies (CMOPs) and Option 2 State Veterans Homes (SVH)), Department of Defense (DoD), Bureau of Prisons (BOP), Indian Health Service (IHS), and Federal Health Care Center (FHCC). VA will award one contract to the responsible offeror who will be able to provide an uninterrupted source of supply for the contracted items. The contract period will be for one year plus four pre-priced one-year option periods. The contract items will be distributed through the VA s and DOD s respective Pharmaceutical Prime Vendor Programs. Offerors must state the exact name (name that appears on label) by which the drug will be supplied and have an NDC number that is unique to the offeror. The successful offeror/contractor's label with its unique NDC shall be the only label on the product. Contractors shall not affix their label over another label on the product. Solicitation #36E79725R0045 will be electronically issued in commercial item format in accordance with FAR Part 12 on or about July 3, 2025, with a tentative closing date of July 17, 2025. The NAICS code for this procurement is 325412. Any future amendments and other miscellaneous documents will be available electronically for download at sam.gov. No paper copies of the solicitation will be available, and no telephone requests for paper copies of the solicitation will be accepted. Interested offerors are advised to continuously check Contracting Opportunities at SAM.gov for any changes to this solicitation. All responsible sources may submit an offer that if timely received, will be considered. The point of contact for this procurement is Chris Carthron. Questions can be e-mailed to Christopher.Carthron@va.gov. The estimated annual requirements are as follows: REQUIREMENT DESCRIPTION ITEM DESCRIPTION PACKAGE SIZE (Syringe/Vial) TOTAL ESTIMATED ANNUAL USAGE (Syringes/Vials) 1 USTEKINUMAB 5MG/ML INJ,SOLN,26ML 1 2,917 2 USTEKINUMAB 45MG/0.5ML,0.5ML 1 8,925 3 USTEKINUMAB 90MG/ML INJ,SYR,1ML 1 38,028 Proposed biosimilar products must be biological products licensed by the FDA under 42 U.S.C 262 and must meet all biosimilar criteria described in 42 U.S.C. 262. Additionally, Biosimilars Products must be FDA approved as a biologic medication that is compared to the innovator (the original biologic) and listed as a biosimilar to the innovator in the FDA Purple Book (https://purplebooksearch.fda.gov/). For any strength/line item in which the offeror has both syringe and vial available commercially, the offeror must offer both the syringe and vial version for that strength/line item; the syringe and vial must be offered at the same price.
From Presolicitation posted on Jun 10, 2025Extension of offer due date.
From Solicitation posted on Jun 24, 2025Updated estimates for line item 3
From Solicitation posted on Jul 16, 2025Notice history
3-
-
Solicitation Posted Jun 24, 2025View changes (4)
- Description: Description was updated
- Notice Type: Presolicitation → Solicitation
- Response Deadline: Not set → Jul 31, 2025
- Set-Aside: None → None
Details
Award Information
Contacts
Contract Specialist